Clinical Trials Browser

Giant Cell Tumor of Bone × 1 year × Clear all

Giant Cell Tumor of Bone

NCT03449108 2025-11-21

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT07227961 2025-11-13

PROMIS and Mobility Evaluation in Sarcoma Patients

Recruiting

800 enrolled

Sarcoma

Alzheimer Disease, Sarcoma, Giant Cell Tumor of Bone

NCT03295981 2025-10-15

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Phase 3 Recruiting

120 enrolled

Giant Cell Tumor of Bone

NCT04586660 2025-10-01

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Phase 4 Active not recruiting

36 enrolled

Giant Cell Tumor of Bone

Clinical Trials

ICG-GCTB

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

PROMIS and Mobility Evaluation in Sarcoma Patients

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone